|Articles|July 1, 2003
Efficacy of Alefacept Treatment in Chronic Plaque Psoriasis
Alefacept is a human LFA-3/IgG1 fusion protein incorporating the external domain of LFA-3, which is expressed on the surface of APCs.4 Alefacept acts by blocking the interaction between LFA-3 and CD2 on the surface of T cells, thereby interfering with the costimulatory step of T-cell activation.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5













